AMENDMENTS TO THE CLAIMS

1. (previsously presented): A method for reducing scarring during the healing of wounds, reducing fibrosis in the treatment of fibrotic conditions, or for preventing or inhibiting scar formation or fibrosis, comprising applying a furin inhibitor to a site of a wound or fibrotic disorder or to a site where a wound may form or fibrosis may occur.

2. (previsously presented): The method defined in claim 1 wherein the inhibitor is a serine protease inhibitor.

3. (previsously presented): The method defined in claim 1 wherein the inhibitor is lipid soluble.

4. (previsously presented): The method defined in claim 2 wherein the inhibitor is a peptidyl chloroalkylketone having a peptide moiety which mimics at least one convertase enzyme cleavage site.

5. (currently ammended): The method defined in claim 2 wherein the inhibitor is decanoyl-RVKR-cmk (SEQ ID NO:1).

6. (previsously presented): The method defined in claim 1 wherein the inhibitor is water soluble.

7. (previsously presented): The method defined in claim 6 wherein the inhibitor is hexa-arginine.

8. (previsously presented): The method defined in claim 15 for treating wounds to inhibit or prevent scar formation.

9. (previsously presented): The method defined in claim 8 for inhibiting or preventing scarring of the eye, nervous tissue or intestines.

10. (previsously presented): The method defined in claim 8 for inhibiting or preventing dermal scarring.

11. (previsously presented): The method defined in claim 8 for inhibiting or preventing scarring following a burn.

12. (previsously presented): The method defined in claim 1 for reducing fibrosis in the treatment of fibrotic conditions.

13. (previsously presented): The method defined in claim 12 wherein the fibrotic condition is a fibrotic disorder selected from glomerulonephritis, cirrhosis of the liver, fibrocytic disease, adhesions or restenosis.

14. (previsously presented): A composition comprising an effective amount of a furin inhibitor for reducing scarring during the healing of wounds, reducing fibrosis in the treatment of fibrotic conditions, or for preventing scar formation or fibrosis, and a pharmaceutically acceptable carrier.

15. (previsously presented): A method of inhibiting the generation of TGF-.beta.1 comprising applying a furin inhibitor to a site where TGF-.beta.1 is generated.

16. (previsously presented): A method of claim 15 wherein said site is a site of platelet activation.

17. (previsously presented): A composition comprising a TGF-.beta.1 generation inhibiting effective amount of a furin inhibitor and a pharmaceutically acceptable carrier.